On Oct. 25, the U.S. Food and Drug Administration (FDA) approved Zohydro ER (hydrocodone bitartrate extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate.
Read more .
FDA approves extended-release, single-entity hydrocodone product
Author(s):
Most Recent Content
For Nurse Practitioners
Quiz: Migraines and Hormones
Women are 2 to 3 times more likely than men to have migraines. Decades ago, these were attributed to women’s inability to cope with...
